Fox Chase Cancer Center News

PHILADELPHIA (December 11, 2023) — Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology (ASH) Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms (MPN).

PHILADELPHIA (December 11, 2023) — Asya Varshavsky-Yanovsky, MD, PhD, an Assistant Professor in the Department of Bone Marrow Transplant and Cellular Therapies at Fox Chase Cancer Center, has presented an analysis showing that the multiple myeloma drug elranatamab is safe and effective for Black or African American patients with relapsed/refractory multiple myeloma (RRMM).

PHILADELPHIA (December 11, 2023) — Edna “Eti” Cukierman, PhD, Co-Leader of the Cancer Signaling and Microenvironment Research Program and Co-Director of The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

PHILADELPHIA (December 11, 2023) — Fox Chase Cancer Center and Fels Cancer Institute for Personalized Medicine researchers will participate in the presentation of six research projects at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held in San Diego, California December 9-12.

PHILADELPHIA (December 1, 2023) — Erica Golemis, PhD, Associate Director for System-wide Integration at Fox Chase Cancer Center and Chair of the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University, was named Editor-in-Chief of Cancer and Metastasis Reviews today.

PHILADELPHIA (November 30, 2023) — Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase Cancer Center, was recently recognized with the Society of Urologic Oncology’s Joseph A. Smith Jr. Mentorship Award.

PHILADELPHIA (November 29, 2023) — A new study co-authored by a researcher from the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center helps explain why drugs targeting a type of enzyme called PIM kinases, which are known to play an important role in several cancers, have largely failed in clinical trials. The findings also indicate that another approach may be significantly more effective.

PHILADELPHIA (November 28, 2023) — Research into alternative therapies for breast and ovarian cancers that contain BRCA1, PALB2, or BRCA2 mutations has focused on developing new drugs targeting an enzyme that helps repair damaged DNA. But a study published in the prestigious journal Nature Communications by researchers at Fox Chase Cancer Center shows that this approach may be most effective for PALB2 and BRCA2 mutation-containing cancers.